Delivery Order SPE2DR25D3301-SPE2DR26F21TP
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $8,559.84 to Amerisourcebergen Drug Corp for the supply of Ibrance 100 mg capsules (21 count) with a completion date of February 4, 2026. This competitive award, issued on January 13, 2026, involves firm fixed-price pricing with no set-aside designation. The product will be delivered to the contractor's facility in Conshohocken, Pennsylvania, where Amerisourcebergen maintains its corporate office and primary distribution operations....
- The Defense Logistics Agency awarded a delivery order valued at $8,559.84 to AmerisourceBergen Drug Corp on January 29, 2026, for the supply of Ibrance 100 mg capsules (21-count units). This non-set-aside, competitively awarded contract represents a firm fixed-price purchase order with performance completion scheduled for February 20, 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal...
- The Defense Logistics Agency awarded a delivery order valued at $8,561.41 to AmerisourceBergen Drug Corp for Ibrance 75 mg capsules (21-count) on November 26, 2025, with a completion date of December 18, 2025. This firm fixed-price delivery order represents a non-competitive set-aside contract and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical...
- The Defense Logistics Agency awarded a delivery order valued at $8,123.96 to AmerisourceBergen Drug Corp for the supply of Ibrance 75 mg capsules (21-count package) on August 1, 2025, with an ultimate completion date of August 22, 2025. The contract is structured as a firm fixed price delivery order with no set-aside designation, meaning it was competitively awarded. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on January 8, 2026, for the supply of Ibrance 75 mg capsules (21-count packaging) valued at $8,561.41, with an ultimate completion date of January 30, 2026. This firm fixed-price delivery order was competitively awarded with no set-aside designation and is being performed at the awardee's Conshohocken, Pennsylvania location. AmerisourceBergen Drug Corp operates as a subsidiary of parent company Cencora, Inc.,...
- The Defense Logistics Agency awarded a $34,245.64 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Ibrance 75 mg capsules (21-count packages) with an ultimate completion date of February 19, 2026. This non-set-aside contract was competitively awarded on January 28, 2026, with performance taking place at the contractor's corporate office in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a subsidiary of Cencora, Inc., is a major pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $17,115.05 to AmerisourceBergen Drug Corp for the supply of Ibrance 100 mg capsules (21-count units) on January 6, 2026, with an ultimate completion date of January 28, 2026. This firm fixed-price, non-set-aside contract is being performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. The delivery order is issued under a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- The Defense Logistics Agency awarded a delivery order valued at $24,367.44 to AmerisourceBergen Drug Corp for the supply of Ibrance 100 mg capsules (21-count package) on August 27, 2025, with an ultimate completion date of September 18, 2025. This competitive award uses firm fixed pricing and carries no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this work at its corporate office location in that...
- On January 28, 2026, the Defense Logistics Agency (DLA) awarded a delivery order valued at $8,555.21 to AmerisourceBergen Drug Corp for the supply of Ibrance 125 mg capsules (21-count packaging). The award, which is expected to be completed by February 19, 2026, carries a firm fixed-price structure with no set-aside designation, indicating the vendor competed on a full and open basis. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is the place of performance for this...
- The Defense Logistics Agency awarded a delivery order valued at $8,559.84 to AmerisourceBergen Drug Corp for the supply of Ibrance 100 mg capsules (21-count packaging) with a firm fixed-price structure. This non-set-aside award was issued on January 12, 2026, with an ultimate completion date of February 3, 2026. The contractor will perform this work from its corporate headquarters location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's parent company...
- SPE2DR25D3301Indefinite Delivery Contract
- SPE2DR25D3301-SPE2DR26F21TPDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $17,119.68 to AmerisourceBergen Drug Corp for Ibrance 100 mg capsules (quantity 21) on February 3, 2026, with completion expected by February 25, 2026. This firm fixed-price contract represents a non-set-aside, competitively awarded procurement structured as a delivery order under an existing contract vehicle. The awardee, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement needs, particularly supporting military and veteran healthcare systems. This delivery order is issued under AmerisourceBergen Drug Corp's parent company Cencora, Inc.'s substantial Indefinite Delivery Contract with DLA Troop Support Medical, valued at up to $999,999,999.00 and extending through December 31, 2031. The IDC functions as a comprehensive global pharmaceutical supply vehicle enabling delivery of brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains to support military treatment facilities and federal healthcare systems worldwide. Ibrance, an oncology medication, exemplifies the specialized pharmaceutical products delivered under this strategic contract vehicle.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $17.1k | 2/2/26 |